Rhythm Pharmaceuticals, Inc. - Common Stock (NQ:RYTM)

86.61 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Rhythm Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Here’s How Much You Would Have Made Owning Rhythm Pharmaceuticals Stock In The Last 5 Years ↗

September 02, 2026

Rhythm Pharmaceuticals (NASDAQ:RYTM) has outperformed the market over the past 5 years by 40.53% on an annualized basis producing an average annual return of 51.66%. Currently, Rhythm Pharmaceuticals...

Via Benzinga

Here's How Much $100 Invested In Rhythm Pharmaceuticals 5 Years Ago Would Be Worth Today ↗

August 31, 2026

Rhythm Pharmaceuticals (NASDAQ:RYTM) has outperformed the market over the past 5 years by 40.99% on an annualized basis producing an average annual return of 52.06%. Currently, Rhythm Pharmaceuticals...

Via Benzinga

Billionaire Stanley Druckenmiller Is Quietly Loading Up on Healthcare Stocks -- Here's What His New Positions Reveal ↗

August 26, 2026

Duquesne Family Office has beefed up its healthcare holdings.

Via The Motley Fool

Eli Lilly and Novo Nordisk Can't Treat This Form of Obesity. Billionaire Stanley Druckenmiller Is Betting Rhythm Pharmaceuticals Can ↗

August 23, 2026

Could this little-known biotech be a hidden gem?

Via The Motley Fool

Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) Surpasses Q1 Estimates as U.S. Hypothalamic Obesity Launch Accelerates ↗

May 05, 2026

Via Chartmill

Rhythm Pharmaceuticals (NASDAQ:RYTM) Posts Q4 Revenue Beat and Narrows Loss ↗

February 26, 2026

Via Chartmill

Rhythm Pharmaceuticals Eyes AHO Growth, Global IMCIVREE Expansion and Pipeline Catalysts ↗

August 17, 2026

Rhythm Pharmaceuticals (NASDAQ:RYTM) is expanding commercialization of its rare-disease obesity treatment IMCIVREE while advancing additional melanocortin-4 receptor, or MC4R, agonists through...

Via MarketBeat

Rhythm Pharmaceuticals (RYTM) Q2 2026 Earnings Call Transcript ↗

August 11, 2026

IMCIVREE revenue surged 19% sequentially as HO patient adoption accelerated post-approval.

Via The Motley Fool

Topics Earnings

Rhythm Pharmaceuticals Q2 Earnings Call Highlights ↗

August 04, 2026

Rhythm Pharmaceuticals (NASDAQ:RYTM) reported second-quarter 2026 global net product sales of $71.3 million for IMCIVREE, up 19% sequentially from $60.1 million in the first quarter, as the company...

Via MarketBeat

Topics Earnings

RYTM Stock Jumps 4% On Imcivree Revenue Growth: Firm Awaits Approval In Acquired Hypothalamic Obesity By March ↗

January 09, 2026

Via Stocktwits

Full Transcript: Rhythm Pharmaceuticals Q2 2026 Earnings Call ↗

August 04, 2026

Rhythm Pharmaceuticals (NASDAQ:RYTM) released second-quarter financial results and hosted an earnings call on Tuesday. Read the complete transcript below. Benzinga APIs provide real-time access to...

Via Benzinga

Topics Earnings

My Top 3 Stocks to Buy in May ↗

May 07, 2026

Forget "sell in May and go away." These stocks are good picks to buy and hold.

Via The Motley Fool

Topics Earnings

Rhythm Pharmaceuticals Analysts Boost Their Forecasts Following Upbeat Q1 Results ↗

May 06, 2026

Rhythm Pharmaceuticals (NASDAQ: RYTM) reported better-than-expected earnings, with strong demand for IMCIVREE and potential launches in Europe and Japan.

Via Benzinga

Rhythm (RYTM) Q1 2026 Earnings Call Transcript ↗

May 06, 2026

Rhythm (RYTM) Q1 2026 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Why Rhythm Pharmaceuticals Stock Triumphed on Tuesday ↗

May 05, 2026

It released an encouraging quarterly earnings report and business update before market open.

Via The Motley Fool

Neurocrine Biosciences to Acquire Celeno Therapeutics in Rare Disease Deal

April 07, 2026

In a move that signals a significant consolidation within the rare endocrine disease market, Neurocrine Biosciences (NASDAQ: NBIX) announced on April 6, 2026, that it has entered into a definitive...

Via MarketMinute

Soleno Therapeutics: A Masterclass in Rare Disease Redemption and the $2.9B Exit

April 07, 2026

The following feature explores the trajectory of Soleno Therapeutics as of April 7, 2026. Introduction On the morning of April 7, 2026, the biotechnology sector is processing one of the most...

Via Finterra

Topics Economy Intellectual Property

Neurocrine Biosciences to Acquire Soleno Therapeutics in $2.9 Billion Deal as VYKAT™ XR Sales Soar

April 06, 2026

Shares of Soleno Therapeutics (NASDAQ: SLNO) surged more than 32% in early trading on Monday, April 6, 2026, following the blockbuster announcement that Neurocrine Biosciences (NASDAQ: NBIX) has...

Via MarketMinute

Topics Intellectual Property

Is This Weight Loss Drug Stock a Buy After a New Approval? ↗

March 31, 2026

This little-known biotech company has a different strategy than the established weight-loss drug market leaders. But is it likely to be successful?

Via The Motley Fool

Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC Filing ↗

March 04, 2026

Immunome develops antibody therapeutics for cancer and infectious diseases, reporting a market cap above $2 billion in the latest filing.

Via The Motley Fool

Topics Regulatory Compliance

Investment Manager Sells $5.1 Million Worth of LQDA Stock, According to Recent SEC Filing ↗

March 04, 2026

Liquidia develops inhaled and injectable therapies for pulmonary arterial hypertension, targeting unmet needs in the U.S. biopharma market.

Via The Motley Fool

Topics Regulatory Compliance

Rhythm Pharma (RYTM) Earnings Call Transcript ↗

February 26, 2026

Rhythm Pharma (RYTM) Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Praxis Stock Surges 320% as One Biotech Investor's Buy Pushes Stake to Nearly $600 Million ↗

February 22, 2026

Praxis Precision Medicines targets neurological and psychiatric disorders with a pipeline of precision therapies for CNS conditions.

Via The Motley Fool

Topics Regulatory Compliance

Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two Position ↗

February 22, 2026

Celcuity develops targeted cancer therapies and diagnostic platforms, with a focus on advancing precision medicine in oncology.

Via The Motley Fool

Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction ↗

February 22, 2026

Apogee Therapeutics develops biologic therapies targeting dermatology and respiratory conditions, with lead candidates in clinical trials.

Via The Motley Fool

Topics Regulatory Compliance

$80 Million Arcellx Sale Follows Steep Stock Drop as Rival Drug Emerges ↗

February 22, 2026

Arcellx develops next-generation cell therapies targeting multiple myeloma and other hematologic cancers in the biotechnology sector.

Via The Motley Fool

Topics Regulatory Compliance

Prediction: These 3 Stocks Will Crush the Market in 2026 ↗

February 16, 2026

These stocks all have catalysts on the way that could provide great news for investors.

Via The Motley Fool

Topics Artificial Intelligence

This High-Flying Growth Stock Is Hiding in Plain Sight ↗

February 02, 2026

This biotech stock is flying under the radar for many investors, but Wall Street loves it.

Via The Motley Fool

The Great Divergence: Why Big Tech Holds the Line While Logistics and Biotech Face a 2026 Reckoning

December 30, 2025

As the curtain closes on 2025, the financial landscape presents a tale of two markets. While the S&P 500 (NYSEARCA: SPY) hovers near the historic 7,000-point milestone, fueled by a 19% year-to-date...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

Rhythm Pharmaceuticals Faces Gravity: FDA Delays and Valuation Pressures Cool 2025’s Biotech Darling

December 30, 2025

As the final trading days of 2025 wind down, Rhythm Pharmaceuticals (Nasdaq: RYTM) finds itself at a critical crossroads. After a meteoric rise that saw the stock gain over 100% through the first three...

Via MarketMinute

Topics ETFs Economy World Trade

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.